Sugi Predict

Sugi Predict / Compounds / SCHEMBL144559

SCHEMBL144559

SCHEMBL144559

Cc1ccc(-c2ccc(F)cc2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ HSD17B1 P14061 2/20 0.48
▸ HSD17B2 P37059 2/20 0.48
▸ FLT3 P36888 2/20 0.41
▸ PGR P06401 1/20 0.41
▸ APP P05067 4/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ GFER P55789 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9927249 0.88 APP (0.48) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL10300218 0.85 APP (0.46) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL13424304 0.85 APP (0.46) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL13376691 0.83 APP (0.50) NPC1ALDH1A1HSD17B1HSD17B2PGR
SCHEMBL12581415 0.83 HSD17B1 (0.63) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL147842 0.81 HSD17B1 (0.44) NPC1ALDH1A1KDM4EHPGDHSD17B1
SCHEMBL12562796 0.80 HSD17B1 (0.61) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL12562851 0.80 HSD17B1 (0.61) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL14817162 0.80 HSD17B1 (0.47) NPC1ALDH1A1KDM4ERAB9AHPGD
SCHEMBL146466 0.79 HSD17B1 (0.61) KDM4EHSD17B1HSD17B2FLT3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109336875-B Synthesis method of canagliflozin 江苏工程职业技术学院 2022-03-11 — — CN claimed
CN-110845469-A Preparation method of canagliflozin intermediate 台州学院 2020-02-28 — — CN claimed
CN-109336875-A A kind of synthetic method of canagliflozin 江苏工程职业技术学院 2019-02-15 — — CN claimed
EP-4206212-A1 SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. (CN) 2023-07-05 — — EP disclosed
CN-113121318-B Biheteroaromatic hydrocarbon compound and preparation method thereof 浙江工业大学 2022-04-26 — — CN disclosed
CN-109336875-B Synthesis method of canagliflozin 江苏工程职业技术学院 2022-03-11 — — CN disclosed
CN-109336875-B Synthesis method of canagliflozin 江苏工程职业技术学院 2022-03-11 — — CN disclosed
CN-113121318-A Biheteroaromatic hydrocarbon compound and preparation method thereof 浙江工业大学 2021-07-16 — — CN disclosed
EP-3251679-B1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-12-16 — — EP disclosed
EP-2896397-B2 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2020-10-07 — — EP disclosed
EP-1651658-B2 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-08-12 — — EP disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
US-7935674-B2 Indole derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7935674-B2 Indole derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7605171-B2 (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists MERCK & CO., INC. (US) 2009-10-20 — — US disclosed
US-20090258921-A1 INDOLE DERIVATIVES NOMURA SUMIHIRO 2009-10-15 — — US disclosed
US-20090258921-A1 INDOLE DERIVATIVES NOMURA SUMIHIRO 2009-10-15 — — US disclosed
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists MERCK & CO., INC. (US) 2008-10-09 — — US disclosed
US-20080119422-A1 Indole Derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-05-22 — — US disclosed
US-20080119422-A1 Indole Derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258921-A1 INDOLE DERIVATIVES IDO1, TPH1, NAT1 NPC1 1438/4885ALDH1A1 241/4885KDM4E 2208/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 NPC1 443/4885ALDH1A1 873/4885KDM4E 2616/4885
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists S1PR1, S1PR3, S1PR5 NPC1 1518/4885ALDH1A1 740/4885KDM4E 2051/4885
US-20080119422-A1 Indole Derivatives IDO1, TPH1, NAT1 NPC1 1438/4885ALDH1A1 241/4885KDM4E 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.